Complete Response Using Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma with Multiple Lymph Node and Bone Metastases: A Case Report

Complete Response Using Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma with Multiple Lymph Node and Bone Metastases: A Case Report

Hepatocellular carcinoma（HCC）is the sixth most commonly diagnosed cancer worldwide. Sorafenib is an oral multikinase inhibitor used in the palliative treatment of advanced HCC. However, there were no reported cases of complete response（CR）from two previous large phaseⅢ clinical trials. Here, we repo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Showa University Journal of Medical Sciences 2019, Vol.31(4), pp.373-378
Hauptverfasser: NOMURA, Norihiro, ITO, Takayoshi, SHINOHARA, Hiroki, SHIMA, Nobukazu, SATOU, Masashi, SAKUMA, Dai, EGUCHI, Junichi, URAGAMI, Naoyuki, DEGUCHI, Yoshio, YOKOYAMA, Noboru, INOUE, Haruhiro
Format: Artikel
Sprache:eng
Schlagworte:
bone metastasis
complete response
hepatocellular carcinoma
sorafenib
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Hepatocellular carcinoma（HCC）is the sixth most commonly diagnosed cancer worldwide. Sorafenib is an oral multikinase inhibitor used in the palliative treatment of advanced HCC. However, there were no reported cases of complete response（CR）from two previous large phaseⅢ clinical trials. Here, we report a case of CR in a patient with advanced HCC with multiple lymph node and bone metastases, treated with sorafenib monotherapy for 8 months. To our knowledge, this is the first evidence showing CR following sorafenib monotherapy for HCC with bone metastasis.
ISSN:0915-6380
2185-0968
DOI:10.15369/sujms.31.373